(8R,9S,10R,13S,14S,17R)-17-乙基-17-羟基-10,13-二甲基-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-3-酮 | 3090-78-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (8R,9S,10R,13S,14S,17R)-17-乙基-17-羟基-10,13-二甲基-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-3-酮
• 中文别名: 1H-吡咯-3-羧酸,2,5-二甲基-4-(4-硝基苯基)-,甲基酯
• 英文名称: 17-hydroxy-pregn-4-en-3-one
• 英文别名: 17-Hydroxy-pregn-4-en-3-on；17alpha-Hydroxy-4-pregnen-3-one；(8R,9S,10R,13S,14S,17R)-17-ethyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 3090-78-6
• 化学式: C₂₁H₃₂O₂
• 分子量: 316.484
• InChiKey: FGPGANCDNDLUST-SJFWLOONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  17,20β_F-epoxy-pregn-4-en-3-one 在 1,4-二氧六环 、 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 (8R,9S,10R,13S,14S,17R)-17-乙基-17-羟基-10,13-二甲基-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-3-酮
  参考文献：
  名称：

  Batres et al., Journal of the American Chemical Society, 1955, vol. 77, p. 4155

  摘要：

  DOI：

文献信息

• MICRONIZED EPLERENONE COMPOSITIONS
  申请人：G.D. SEARLE & CO.

  公开号：EP1135139A1

  公开（公告）日：2001-09-26
• COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS
  申请人：The Hospital For Sick Children

  公开号：EP2598150A2

  公开（公告）日：2013-06-05
• Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
  申请人：Hyde Roderick A.

  公开号：US20100022489A1

  公开（公告）日：2010-01-28

  A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.
• System and device for maintaining physiological levels of steroid hormone in a subject
  申请人：Hyde Roderick A.

  公开号：US20100022991A1

  公开（公告）日：2010-01-28

  A system, device, or method is provided which maintains a substantially physiological level or a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The system, device, or method includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The system, device, or methods can be used for the treatment of a disease or condition in the mammalian subject.
• Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
  申请人：Hyde Roderick A.

  公开号：US20100022497A1

  公开（公告）日：2010-01-28

  A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the subject.